ATP5F1B and metastatic neoplasm: This suggests that patients with disomy 3 and low ATP5F1B expression have a reduced risk of metastatic disease vs. patients with disomy 3 and high ATP5F1B. This preclinical data solidifies the role of CysLT1 expression as a poor prognostic indicator and offers prognostic potential for ATP5F1B in combination with disomy 3 in primary UM tumours.